The Future of Muscular Dystrophy Management: Updates for Duchenne Muscular Dystrophy

Published: June 27, 2023, 4 a.m.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
\n\n Guest: Julie Parsons, MD
\n\n Guest: Craig Zaidman, MD
\n\n\n \n

Duchenne Muscular Dystrophy, or DMD, is considered a rare disease, affecting 1 in 3,500 boy births. But to the patients afflicted-and to the families who love them-it is a painful, everyday experience. Current advances in gene transfer therapy are exciting. Helping clinicians interpret and utilize the outcomes of gene therapy clinical trials is critical to effective treatment and management of DMD, as is the coordination of multidisciplinary teams for the ongoing care of these patients.